Immune Response News and Research

RSS

Researchers uncover potential new target for anti-COVID-19 therapies

Researchers from Cleveland Clinic's Florida Research and Innovation Center have identified a potential new target for anti-COVID-19 therapies.

16 Mar 2021

Combination therapy may reduce influenza-associated morbidity and mortality

A significant proportion of hospitalized patients with influenza develop complications of acute respiratory distress syndrome, driven by virus-induced cytopathic effects as well as exaggerated host immune response.

16 Mar 2021

Study explores how SARS-CoV-2 mutations produce antibody resistance and enhanced transmissibility

An interesting new study deals with the effects of the natural mutations in the spike antigen of the SARS-CoV-2, the pathogen that is responsible for the ongoing coronavirus disease pandemic.

16 Mar 2021

The role of RNA capping of SARS-CoV-2 in immunity evasion

The SARS-CoV-2 pathogen successfully uses multiple immune evasion mechanisms to achieve infection within its host. An intriguing new study describes one such process, which may help develop drugs to counteract the virus more effectively.

16 Mar 2021

New Phase 1 study evaluates prime/boost HIV-1 vaccine formulated with combinations of adjuvants

A new Phase 1 vaccine study began today that will evaluate experimental prime/boost HIV-1 vaccine regimens formulated with combinations of different adjuvants, including one from the Army Liposome Formulation (ALF) family of adjuvants developed by scientists with the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research.

15 Mar 2021

New cancer immunotherapy uses engineered T cells to target a common genetic alteration

Researchers developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers.

15 Mar 2021

Discovery may help cancer patients to avoid chemotherapy's debilitating side effects

A discovery by University of Queensland pain researchers may allow some future cancer patients, including children with leukemia, to avoid their chemotherapy's worst and most debilitating side effects.

15 Mar 2021

What is a protective neutralizing antibody titer against SARS-CoV-2 infection?

A new study describes a predictive model of protective immunity against SARS-CoV-2 infection that could help evolve optimal vaccination strategies to maintain protection and reduce the death rate.

15 Mar 2021

Why does convalescent plasma therapy for severe COVID-19 show mixed success?

A surprising new preprint, released on the medRxiv* server, suggests that the beneficial effects of convalescent plasma (CP) in this disease stem not only from the presence of neutralizing antibodies, but also the immunomodulatory effects of this plasma that shapes the host immune response.

15 Mar 2021

Which biomarkers can help predict severe COVID-19?

The ability to detect potentially fatal illness early on in the course of the disease would enable a swift prioritization of these high-risk individuals for treatment. A new preprint on the medRxiv* server presents an array of biomarkers that may help achieve this laudable goal.

15 Mar 2021

Research looks at inflammatory nature of lipid nanoparticle component in mRNA vaccines

In a recent bioRxiv preprint research paper, Botond Z. Igyártó and colleagues from Thomas Jefferson University demonstrated the inflammatory nature of the lipid nanoparticles (LNPs).

15 Mar 2021

Genome-wide CRISPR screening used to identify factors essential for SARS-CoV-2 infection in humans

In a methodologically trailblazing paper published in the journal Nature Genetics, a team of Belgian scientists uncovered an assembly of coronavirus host factors that may be exploited to develop drugs against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also potentially forthcoming zoonotic coronaviruses.

14 Mar 2021

Study maps crucial component of long-term immune response to SARS-CoV-2

Researchers in the United States have found that protective antibodies generated against the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)– the agent that causes coronavirus disease 2019 (COVID-19) – also protect against viral variants.

14 Mar 2021

Cannabis compound inhibits SARS-CoV-2 replication in human lung cells

Researchers in the United States have conducted a study showing that a cannabis plant compound inhibited infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human lung cells.

14 Mar 2021

New vaccination method aims at comprehensive protection against all known influenza mutations

One shot, protected forever: This would be a dream come true regarding influenza vaccinations. So far, vaccination against influenza did not provide a lasting protection.

13 Mar 2021

Neutralizing antibodies induced by COVID-19 vaccines less effective against new variants

SARS-CoV-2, the virus that causes COVID-19, has mutated throughout the pandemic. New variants of the virus have arisen throughout the world, including variants that might possess increased ability to spread or evade the immune system.

13 Mar 2021

SARS-CoV-2 did not change much when it jumped from bats to human hosts

How much did SARS-CoV-2 need to change in order to adapt to its new human host? In a research article published in the open access journal PLOS Biology Oscar MacLean, Spyros Lytras at the University of Glasgow, and colleagues, show that since December 2019 and for the first 11 months of the SARS-CoV-2 pandemic there has been very little 'important' genetic change observed in the hundreds of thousands of sequenced virus genomes.

13 Mar 2021

Immune Response News and Research

Researchers uncover potential new target for anti-COVID-19 therapies

Combination therapy may reduce influenza-associated morbidity and mortality

Study explores how SARS-CoV-2 mutations produce antibody resistance and enhanced transmissibility

The role of RNA capping of SARS-CoV-2 in immunity evasion

New Phase 1 study evaluates prime/boost HIV-1 vaccine formulated with combinations of adjuvants

New cancer immunotherapy uses engineered T cells to target a common genetic alteration

Discovery may help cancer patients to avoid chemotherapy's debilitating side effects

What is a protective neutralizing antibody titer against SARS-CoV-2 infection?

Why does convalescent plasma therapy for severe COVID-19 show mixed success?

Which biomarkers can help predict severe COVID-19?

Research looks at inflammatory nature of lipid nanoparticle component in mRNA vaccines

Genome-wide CRISPR screening used to identify factors essential for SARS-CoV-2 infection in humans

Study maps crucial component of long-term immune response to SARS-CoV-2

Cannabis compound inhibits SARS-CoV-2 replication in human lung cells

New vaccination method aims at comprehensive protection against all known influenza mutations

Neutralizing antibodies induced by COVID-19 vaccines less effective against new variants

SARS-CoV-2 did not change much when it jumped from bats to human hosts

How common are post-acute sequelae of SARS-CoV-2 infection?

Natural virus-induced immunity protective against UK and South African SARS-CoV-2 variants in hamster study

Scientists increase potency of HIV-1 antibody, identify new ways to develop vaccines

Understanding the DNA Damage Response in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News